全文获取类型
收费全文 | 1598697篇 |
免费 | 133555篇 |
国内免费 | 2575篇 |
专业分类
耳鼻咽喉 | 21643篇 |
儿科学 | 52911篇 |
妇产科学 | 46226篇 |
基础医学 | 227712篇 |
口腔科学 | 47185篇 |
临床医学 | 140785篇 |
内科学 | 314447篇 |
皮肤病学 | 34088篇 |
神经病学 | 130049篇 |
特种医学 | 64713篇 |
外国民族医学 | 474篇 |
外科学 | 243767篇 |
综合类 | 39703篇 |
现状与发展 | 3篇 |
一般理论 | 544篇 |
预防医学 | 122720篇 |
眼科学 | 36442篇 |
药学 | 121219篇 |
2篇 | |
中国医学 | 2974篇 |
肿瘤学 | 87220篇 |
出版年
2018年 | 14761篇 |
2016年 | 12896篇 |
2015年 | 15024篇 |
2014年 | 20646篇 |
2013年 | 31349篇 |
2012年 | 42545篇 |
2011年 | 44749篇 |
2010年 | 26336篇 |
2009年 | 25303篇 |
2008年 | 42995篇 |
2007年 | 45239篇 |
2006年 | 46048篇 |
2005年 | 44671篇 |
2004年 | 44088篇 |
2003年 | 42177篇 |
2002年 | 41291篇 |
2001年 | 75683篇 |
2000年 | 78326篇 |
1999年 | 66387篇 |
1998年 | 17731篇 |
1997年 | 16334篇 |
1996年 | 16314篇 |
1995年 | 16019篇 |
1994年 | 15070篇 |
1993年 | 14218篇 |
1992年 | 55427篇 |
1991年 | 53775篇 |
1990年 | 52561篇 |
1989年 | 50832篇 |
1988年 | 47221篇 |
1987年 | 46561篇 |
1986年 | 44284篇 |
1985年 | 42843篇 |
1984年 | 32033篇 |
1983年 | 27565篇 |
1982年 | 16144篇 |
1981年 | 14436篇 |
1980年 | 13564篇 |
1979年 | 30460篇 |
1978年 | 21064篇 |
1977年 | 17764篇 |
1976年 | 16694篇 |
1975年 | 17574篇 |
1974年 | 21486篇 |
1973年 | 20672篇 |
1972年 | 18853篇 |
1971年 | 17770篇 |
1970年 | 16289篇 |
1969年 | 15268篇 |
1968年 | 13949篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
231.
232.
233.
234.
235.
Brenda Laky Isabella Alram Julia K. Frank Leo Pauzenberger Werner Anderl Karl-Heinz Wagner Philipp R. Heuberer 《Journal of orthopaedic research》2020,38(9):2074-2082
Increasing numbers of arthroplasties are also accompanied by postoperative infections. The main purpose was to evaluate preoperative serum bilirubin levels between patients with and without infections after shoulder and knee arthroplasties. For this retrospective case-control single-center study, a total of 108 patients were extracted from a prospectively collected database. Eighteen patients with infections after shoulder (n = 8) and knee (n = 10) arthroplasty were matched by age, gender, and implant type in a 1:5-scenario to 90 patients (40 shoulders and 50 knees) without postoperative infection. Demographic data, preoperative blood parameters, and postoperative infection-related outcomes were evaluated. Total bilirubin was the only preoperative parameter significantly different between the infection (8.21 ± 3.25 μmol/L or 0.48 ± 0.19 mg/dL) and noninfection (10.78 ± 4.62 μmol/L or 0.63 ± 0.27 mg/dL; P = .014) group, while C-reactive protein and other liver parameters were similar between the groups. Significantly more controls (92.1%) had preoperative bilirubin levels above 8.72 μmol/L or 0.51 mg/dL than cases (7.9%; P = .007). The 5-year infection survival-rate was 65.6% for patients with preoperative bilirubin levels < 8.72 μmol/L or < 0.51 mg/dL and 91.2% with ≥ 8.72 μmol/L or ≥ 0.51 mg/dL. Mildly decreased preoperative bilirubin levels with a cutoff at 8.72 μmol/L or 0.51 mg/dL were significantly associated to patients with infections after shoulder and knee arthroplasty. There were no differences in other blood parameters or comorbidities between patients with infections and their matched-controls. 相似文献
236.
A. Prado Rodríguez R. Mato Búa L. Mera Mujico J. Arca Suárez M. López Sánchez L. Sampayo Rodríguez P. Rama-Maceiras 《Revista espa?ola de anestesiología y reanimación》2021,68(6):361-366
Serum lactate is a non-specific marker of tissue hypoperfusion. Elevated serum lactate is used in the differential diagnosis of acute intestinal ischemia. Although this practice is controversial, in the absence of other validated markers lactate is still used because of its high sensitivity.We present the cases of two patients who developed acute mesenteric ischemia as a post-surgical complication. The patients reported moderate abdominal pain —a non-specific symptom in the postoperative context— and tests showed progressively increasing serum lactate levels, which facilitated suspicion and subsequent diagnostic confirmation through an imaging test.These cases highlight the physiopathological importance of lactate elevation in the perioperative context and of performing a differential diagnosis of its possible causes, including mesenteric ischemia. Although the outcome was negative in the first case, early suspicion allowed us to make an effective diagnosis and administer appropriate treatment in the second patient. 相似文献
237.
Rosario Fernández-Plata Rogelio Pérez-Padilla Rodrigo Del Río-Hidalgo Cecilia García-Sancho Laura Gochicoa-Rangel Christian Rodríguez-Hernández Luis Torre-Bouscoulet David Martínez-Briseño 《Archivos de bronconeumología》2019,55(10):513-518
IntroductionPeople with Down syndrome (DS) have high respiratory morbidity, evaluating their respiratory health with standardized, objective tests is desirable. Thus, the objective of this study was to evaluate the technical quality of Pulmonary Function Tests (PFTs) to determine which ones are most suitable for this population.MethodsParticipants included children, teenagers and adults with DS, 5 years of age or older (n = 302). The technical quality of the impulse oscillometry system (IOS), forced spirometry, lung-diffusing capacity for carbon monoxide (DLCO), and 6-min walk test (6MWT) were analyzed by age group. Capnography and pulse oximetry were included in the study. Technical quality was determined on the basis of current international PFTs standards.ResultsFifty-one percent of participants were males. A total of 184 participants (71%) who completed the IOS fulfilled the quality criteria, while 210 (70%) completed the 6MWT. Performance on forced spirometry and DLCO was poor. All pulse oximetries and 96% percent heart rates obtained had good quality, but exhaled carbon dioxide (PetCO2) and respiratory rate (RR) showed deficient repeatability.ConclusionsIOS appears to be the most reliable instrument for evaluating lung mechanics in individuals with DS. 相似文献
238.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
239.
240.
J.J. Crowley R.B. Warren J.C. Cather 《Journal of the European Academy of Dermatology and Venereology》2019,33(9):1676-1684
Psoriasis is a chronic disease that requires long‐term treatment. Consequently, understanding the safety and tolerability of any potential treatment over time is critical to effective prescribing. The biologic agents currently available for the treatment of psoriasis target a number of different inflammatory cytokines involved in psoriasis disease pathogenesis. The monoclonal antibodies tildrakizumab, guselkumab and risankizumab target the p19 subunit that is specific to interleukin (IL)‐23. This article reviews published data on the safety of these IL‐23p19 inhibitors in patients with psoriasis compared with other currently available biologic therapies. Data from randomized, placebo‐ and active‐controlled phase 3 clinical trials show tildrakizumab, guselkumab and risankizumab to have a favourable risk–benefit profile in patients with moderate to severe psoriasis. No significant safety concerns have been observed for any of these IL‐23p19 inhibitors in the data published to date. The most commonly reported adverse events (AEs) associated with these agents in phase 3 studies were upper respiratory tract infections. No increase was seen in rates of serious infections, malignancies or major adverse cardiovascular events, with no signals suggestive of an elevated risk of opportunistic infections, active tuberculosis or reactivation of latent tuberculosis infection, mucocutaneous Candida infections, triggering or worsening of inflammatory bowel disease, demyelinating disorders or suicidal ideation. Selectively targeting IL‐23p19 may help avoid AEs that have been associated with biologic agents with other mechanisms of action. Data from long‐term extension studies and patient registries will further establish the safety profile of IL‐23p19 inhibitors for the treatment of moderate to severe psoriasis in routine practice. 相似文献